Ensuring Equitable and Patient-Centered Healthcare Policymaking
Analyze how state and federal health care policies and funding affect health care organizations and consumers.
Reflection
Pick a proposed rule from Centers for Medicare & Medicaid Services Federal Policy Guidance.
Reflect on the following in a minimum of 500 words:
Are there any cultural sensitivities that need to be considered because of the notice, rule, or proposed rule?
Should all cultures be given equal consideration in health care policies?
What aspects of culture should be given consideration in the health care industry?
Ensuring Equitable and Patient-Centered Healthcare Policymaking
Student Name
Institutional Affiliation
Course Code
Instructor
Date
Patient-centered care has continued being a crucial element of the healthcare system and practices in the country. The U.S.A healthcare system continues experiencing a lot of changes due to the ever-changing sociocultural dynamics. Over the past several decades, new generations have come up, spurred by new communities from both within and outside the country. These demographic changes have brought with them new insights into the healthcare system. The most significant of them is how health is supposed to be delivered with respect to the cultural orientation of the patients coming in. with the generally greater number of diverse cultures around, healthcare providers need to also make significant adjustments to suit the population. There is need for tailored healthcare practices that is strictly patient-centered.
The Medicaid proposed rule titled "Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) Programs and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements" (Federal Policy Guidance | medicaid.gov, 2023) aims to advance pharmacy quality, however, it overlooks key cultural perspectives. Specifically, the rule seeks to promote value-based purchasing arrangements between drug manufacturers and payers to lower costs. However, it does not sufficiently account